ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

Carrington Launches New Corporate Website

Print | 
Email |  Comment   Share  

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)

Carrington Laboratories, Inc.
2001 Walnut Hill Lane
Irving, TX, 75038
USA



Press release date: January 11, 2007

oIncrease Corporate Awareness o Easier to Access DelSite's Website o Internet Marketing Campaign to Follow

IRVING, Texas, Jan. 11 -- Carrington Laboratories, Inc., (NASDAQ:CARN) today announced they have launched a new corporate website. The redesigned website is located at Carrington's current URL of http://www.carringtonlabs.com/ and contains new features such as site search functionality, improved navigation, and updated information on Carrington's products and services. New pages have also been added containing information on Carrington's subsidiaries and other markets such as veterinary and oral care products. The online shopping cart has also been redesigned to make it much easier to purchase Carrington's products via the web.

DelSite Biotechnologies, Inc., Carrington's drug delivery subsidiary, has more visibility and information related to its development of a nasal powder vaccine using its GelVac(TM) formula with the H5N1 (bird flu) antigen. Potential partners now have several points to access the DelSite website, http://www.delsite.com/ . Links are available throughout the site including, a prominent logo located on the bottom right hand side of the homepage, through the drug delivery sections under Markets We Serve and Research, and through the Subsidiaries page.

"Over the past six months, Carrington has been analyzing our market presence and strategy of all our business segments and brands. One consistent theme that continued to come up from potential customers and partners was our website," stated Mr. Doug Golwas, Vice President of Corporate Sales and Marketing. "It did not accurately reflect our company's image and contained little information on who we are and what we do. The new website has addressed these concerns and portrays Carrington as what it is, a research- oriented, global supplier of health products."

In conjunction to launching the redesigned website, Carrington will be implementing an Internet marketing campaign to build awareness of its brands and services. The Internet marketing campaign will consist of search engine optimization, pay-per-click advertisements, banner advertisements with industry organizations, an email marketing initiative and an online customer retention program. By combining the Internet marketing campaign with the new website, Carrington hopes to reach out to a larger group of customers and improve communication with existing customers and partners.

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from the Department of Health and Human Services. In September of 2006, DelSite entered into a three-year CRADA with the Laboratory of Cellular Oncology at the National Cancer Institute (NCI) to determine if GelVac(TM) nasal powder delivery platform is adaptable for delivering human papillomavirus virus-like particles (HPV VLP) vaccines in a powder dosage form for mucosal immunization.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite Biotechnologies, a subsidiary of Carrington, is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com/ .

Source: Carrington Laboratories, Inc.

CONTACT: Doug Golwas, VP, Corp. Sales & Mktg of Carrington Laboratories, Inc., +1-972-518-1300

Web site: http://www.carringtonlabs.com/ http://www.delsite.com/
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


User comments about this story

mannose

Do you still sell mannose directly to customers.
Thanks

By Larry Mefforde on Apr 3, 2014 21:48

Reply to this comment


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



| Featured Manufacturing Jobs
 Other News from this company:
Carrington Subsidiary DelSite Demonstrates Usefulness of GelSiteŽ Polymer for Therapeutic Delivery of Proteins and Peptides at Controlled Release Society Meeting
Carrington Signs Term Sheet with AM Labs for Distribution of Oral Products to Retail Markets
Carrington and Racing Legend Johnny Rutherford Sign Endorsement and Personal Services Agreement
Carrington Subsidiary in Pact for Development of Vaccine for Bacillary Dysentery (Shigellosis) Using DelSite's Nasal Powder Delivery System
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story


Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy



Error close

Please enter a valid email address